Chromatin regulatory pathways are frequently dysregulated in cancer. Cancer genomic sequencing campaigns have led to the identification of recurrent genomic abnormalities in genes that encode for chromatin regulators, supporting the concept that transcriptional reprogramming in cancer cells is in part achieved by the manipulation of chromatin structure. Moreover, individual chromatin regulators are overexpressed in cancer cells, consistent with the aberrant chromatin modification profiles frequently observed in cancer cells.

Recurrent somatic mutations in individual cancer types and across a number of cancer types
Recurrent somatic mutations in individual cancer types and across a number of cancer types

Constellation Pharmaceuticals, Inc.
215 First Street, Suite 200
Cambridge, MA 02142

For Media Inquiries
Katie Engleman
W2Opure
katie@purecommunications.com
+1 (910) 509-3977

For General Inquires
To request additional information please use:
info@constellationpharma.com
Phone: (617) 714-0555
Fax: (617) 577-0472